Most Read Articles
01 Oct 2017
Antidepressants may be effective for treating depression in patients with schizophrenia, according to a meta-analysis that underscores qualifying conclusions based on the small number of low- or moderate-quality studies.
Rachel Soon, 01 Mar 2018

Unregulated online sales of products containing controlled medicines must be curbed in the name of consumer safety, warns the Malaysian Pharmaceutical Society (MPS).

10 Apr 2018
Antiviral treatment for colonic cytomegalovirus (CMV) infection significantly improves short- and long-term surgery-free survival in patients with ulcerative colitis (UC), according to the results of a small-scale study.
Audrey Abella, 03 Oct 2017
Once-monthly and once-quarterly administration of paliperidone palmitate had similar efficacy in terms of relapse prevention for schizophrenia in an East Asian population, according to a subgroup analysis.

About half of CVD patients could be eligible for PCSK9 inhibitors

10 Jan 2018

About half of patients with cardiovascular disease (CVD) may be eligible for proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor therapy and results from a study of a large Canadian population-based cohort show such therapy may prevent CV events, though with significant costs. [Ko DT, et al, AHA 2017, abstract 778]

Among 62,729 adult patients with CVD, 61 percent, or 2.6 percent of the general population, were eligible for PCSK9 inhibitors based on eligibility criteria of the FOURIER trial (ie, fasting LDL-cholesterol 70 mg/dL or non–HDL-cholesterol ≥100 mg/dL while on an optimized lipid-lowering regimen).

“Applying the FOURIER hazard ratio to our study, we found a reduction in primary outcome [CV death, MI, unstable angina, stroke or coronary revascularization] of about 1.3 percent with PCSK9 inhibitors, which is similar to results of the FOURIER study,” said lead researcher Dr Dennis Ko of the Institute for Clinical Evaluative Sciences in Toronto, Ontario, Canada. 

“This was associated with a high cost per event,” he added, noting that the anticipated absolute clinical benefit in their trial may be smaller than reported in other PCSK9 inhibitor trials because of low overall event rates.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Oct 2017
Antidepressants may be effective for treating depression in patients with schizophrenia, according to a meta-analysis that underscores qualifying conclusions based on the small number of low- or moderate-quality studies.
Rachel Soon, 01 Mar 2018

Unregulated online sales of products containing controlled medicines must be curbed in the name of consumer safety, warns the Malaysian Pharmaceutical Society (MPS).

10 Apr 2018
Antiviral treatment for colonic cytomegalovirus (CMV) infection significantly improves short- and long-term surgery-free survival in patients with ulcerative colitis (UC), according to the results of a small-scale study.
Audrey Abella, 03 Oct 2017
Once-monthly and once-quarterly administration of paliperidone palmitate had similar efficacy in terms of relapse prevention for schizophrenia in an East Asian population, according to a subgroup analysis.